Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.
TipRanks on MSN19h
Lantheus Holdings Inc. Reports Strong Growth and Strategic MovesLantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue ...
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...
Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...
LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...
Lantheus (NASDAQ:LNTH – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, ...
Good morning. Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Argenx Se ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback